NO20083160L - Methods for obtaining immortalized anitbody secreting cells - Google Patents

Methods for obtaining immortalized anitbody secreting cells

Info

Publication number
NO20083160L
NO20083160L NO20083160A NO20083160A NO20083160L NO 20083160 L NO20083160 L NO 20083160L NO 20083160 A NO20083160 A NO 20083160A NO 20083160 A NO20083160 A NO 20083160A NO 20083160 L NO20083160 L NO 20083160L
Authority
NO
Norway
Prior art keywords
methods
cells
human
anitbody
secrete
Prior art date
Application number
NO20083160A
Other languages
English (en)
Norwegian (no)
Inventor
Marianne Murphy
Ada Funaro
Gianni Garotta
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of NO20083160L publication Critical patent/NO20083160L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
NO20083160A 2005-12-16 2008-07-15 Methods for obtaining immortalized anitbody secreting cells NO20083160L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005056871 2005-12-16
PCT/EP2006/069780 WO2007068758A1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells

Publications (1)

Publication Number Publication Date
NO20083160L true NO20083160L (no) 2008-09-10

Family

ID=36685876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083160A NO20083160L (no) 2005-12-16 2008-07-15 Methods for obtaining immortalized anitbody secreting cells

Country Status (20)

Country Link
US (1) US8338172B2 (ru)
EP (1) EP1974020B1 (ru)
JP (2) JP5431730B2 (ru)
KR (1) KR101508945B1 (ru)
CN (1) CN101374944B (ru)
AT (1) ATE513034T1 (ru)
AU (1) AU2006325236B2 (ru)
BR (1) BRPI0619908A2 (ru)
CA (1) CA2633601C (ru)
DK (1) DK1974020T3 (ru)
EA (1) EA019505B1 (ru)
ES (1) ES2367322T3 (ru)
HK (1) HK1127783A1 (ru)
IL (1) IL192095A0 (ru)
NO (1) NO20083160L (ru)
NZ (1) NZ569816A (ru)
PL (1) PL1974020T3 (ru)
PT (1) PT1974020E (ru)
WO (1) WO2007068758A1 (ru)
ZA (2) ZA200806094B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
JP5797403B2 (ja) * 2007-08-03 2015-10-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトモノクローナル抗体およびそれを産生する方法
EP2190876A1 (en) * 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
PE20110413A1 (es) 2008-07-16 2011-06-25 Inst Research In Biomedicine Anticuerpos neutralizantes de la glicoproteina b de citomegalovirus humano
WO2010034103A1 (en) 2008-09-23 2010-04-01 Héma-Québec Method for polyclonal immunoglobulin g production by human b cells
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
SG181901A1 (en) 2009-12-23 2012-08-30 4Antibody Ag Binding members for human cytomegalovirus
EP2400298B1 (en) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
CN106188284B (zh) 2010-07-09 2020-05-08 扬森疫苗与预防公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
CN102839152A (zh) * 2011-06-20 2012-12-26 中国科学院上海生命科学研究院 一种快速高效获得抗原特异性b细胞的方法
US20140287402A1 (en) 2011-06-27 2014-09-25 Valneva Method for screening cells
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US9957319B2 (en) * 2011-12-28 2018-05-01 Immunoqure Ag Method of isolating human antibodies
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
US20140199319A1 (en) * 2012-12-14 2014-07-17 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
JP6421944B2 (ja) * 2013-01-03 2018-11-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ サッカロミセス・セレビシエでの発現によって分泌可能な抗体を製造する方法
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110121554B (zh) * 2017-01-02 2023-08-15 豪夫迈·罗氏有限公司 B细胞培养方法
AU2018213378A1 (en) 2017-01-27 2019-08-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN117230258B (zh) * 2023-11-10 2024-04-09 苏州驾玉生物医药有限公司 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
CA2066720A1 (en) * 1989-09-19 1991-03-20 David M. Knight Method for improving human monoclonal antibody production
DK0440147T3 (da) * 1990-02-01 2005-01-17 Dade Behring Marburg Gmbh Fremstilling og anvendelse af genbanker af humant antistof ("humant-antistof-biblioteker")
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
FR2817875B1 (fr) * 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
WO2007049152A2 (en) * 2005-08-23 2007-05-03 Iq Corporation Methods of producing stable b-lymphocytes

Also Published As

Publication number Publication date
NZ569816A (en) 2011-10-28
WO2007068758A1 (en) 2007-06-21
JP2009519026A (ja) 2009-05-14
KR20080097181A (ko) 2008-11-04
EA019505B1 (ru) 2014-04-30
ES2367322T3 (es) 2011-11-02
ZA200904907B (en) 2010-04-28
US8338172B2 (en) 2012-12-25
AU2006325236B2 (en) 2011-11-10
PT1974020E (pt) 2011-08-26
CA2633601A1 (en) 2007-06-21
CA2633601C (en) 2015-06-30
KR101508945B1 (ko) 2015-04-08
US20090270268A1 (en) 2009-10-29
BRPI0619908A2 (pt) 2011-10-25
EA200870062A1 (ru) 2009-04-28
ATE513034T1 (de) 2011-07-15
AU2006325236A1 (en) 2007-06-21
HK1127783A1 (en) 2009-10-09
PL1974020T3 (pl) 2011-11-30
CN101374944A (zh) 2009-02-25
ZA200806094B (en) 2009-06-24
CN101374944B (zh) 2012-02-08
JP2013255515A (ja) 2013-12-26
DK1974020T3 (da) 2011-10-03
IL192095A0 (en) 2008-12-29
EP1974020A1 (en) 2008-10-01
JP5431730B2 (ja) 2014-03-05
EP1974020B1 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
NO20083160L (no) Methods for obtaining immortalized anitbody secreting cells
US20210189343A1 (en) Soluble Antibody Complexes for T Cell or NK Cell Activation and Expansion
Tsioris et al. Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing
Cao et al. B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
Gundry et al. A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells
MX2019013184A (es) Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
MX2020000900A (es) Reactivos para expandir celulas que expresan receptores recombinantes.
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
DE60232895D1 (de) Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
Gu et al. Global expression of cell surface proteins in embryonic stem cells
WO2009035738A3 (en) Use of antibody secreting cell elispot to assess antibody responses following antigen exposure
Dang et al. Soluble CD27 induces IgG production through activation of antigen‐primed B cells
BR112021020426A2 (pt) Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso
Correa et al. Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
WO2011050985A8 (en) Clonal expansion of b cells
Vasquez et al. Rapid proliferation and differentiation of a subset of circulating IgM memory B cells to a CpG/cytokine stimulus in vitro
Scholzen et al. Expansion of IgG+ B-cells during mitogen stimulation for memory B-cell ELISpot analysis is influenced by size and composition of the B-cell pool
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.
WO2009045075A3 (en) A monoclonal antibody specific to human embryonic stem cell, a hybridoma secreting the same and a method for detecting or isolating non-differenced embryonic stem cell
DE602005022757D1 (de) Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
WO2018232278A3 (en) PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE
Azimi CAR Pooling: High throughput screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
Al Zayer et al. P080 Case report, BANFF III rejection with IGM-donor specific antibody (DSA)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application